文献速递神经肿瘤

纳武利尤单抗治疗复发非典型/间变性脑膜瘤的II期试验结果

Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.
PubMed 文献 · Neuro Oncol · 2022-01-01

6个月无进展生存率为42.4%(95%CI:22.8,60.7),中位总生存期为30.9个月(95%CI:17.6,NA),1例患者达到影像学缓解并持续4.5年。纳武利尤单抗耐受性良好,但未能改善PFS-6,仅部分患者似乎获益。

要点

  • 纳武利尤单抗耐受性良好,未出现非预期不良事件,但整体未改善PFS-6。
  • PFS-6为42.4%,中位OS为30.9个月,1例影像学缓解持续4.5年。
  • 肿瘤突变负荷与TIL密度普遍偏低,NANO量表可用于神经功能结局评估。

核心结论

  • 纳武利尤单抗耐受性良好但未能改善PFS-6,部分患者似乎获益,未来可考虑合理设计的联合方案。

主要发现

  • 6个月无进展生存率为42.4%(95%CI:22.8,60.7),中位总生存期为30.9个月(95%CI:17.6,NA)。
  • 1例患者达到影像学缓解,缓解持续4.5年。
  • 15例可评估肿瘤中2例TMB>10/Mb(13.3%);基线TIL密度低,治疗后3例升高,其中包括2例TMB升高者。
  • 多数达到PFS-6的患者在进展前NANO评估的神经功能维持稳定。

关键数值与推荐

  • 纳武利尤单抗剂量为240 mg,每两周一次。
  • 60%患者既往≥3次手术,72%患者既往≥2程放疗。

临床怎么用

  • 对复发高级别脑膜瘤,纳武利尤单抗单药不作为常规推荐,可考虑在临床试验中探索联合方案。
  • NANO量表可用于前瞻性评估神经功能并辅助结局判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed death ligand 1 (PD-L1) contributes to tumor immunosuppression and is upregulated in aggressive meningiomas. We performed a phase II study of nivolumab, a programmed death 1 (PD-1) blocking antibody among patients with grade ≥2 meningioma that recurred after surgery and radiation therapy. METHODS: Twenty-five patients received nivolumab (240 mg biweekly) until progression, voluntary withdrawal, unacceptable toxicity, or death. Tumor mutational burden (TMB) and quantification of tumor-infiltrating lymphocytes (TIL) were evaluated as potential immunocorrelative biomarkers. Change in neurologic function was prospectively assessed using the Neurologic Assessment in Neuro-Oncology (NANO) scale. RESULTS: Enrolled patients had multiple recurrences including ≥3 prior surgeries and ≥2 prior courses of radiation in 60% and 72%, respectively. Nivolumab was well tolerated with no unexpected adverse events. Six-month progression-free survival (PFS-6) rate was 42.4% (95% CI: 22.8, 60.7) and the median OS was 30.9 months (95% CI: 17.6, NA). One patient achieved radiographic response (ongoing at 4.5 years). TMB was >10/Mb in 2 of 15 profiled tumors (13.3%). Baseline TIL density was low but increased posttreatment in 3 patients including both patients with elevated TMB. Most patients who achieved PFS-6 maintained neurologic function prior to progression as assessed by NANO. CONCLUSION: Nivolumab was well tolerated but failed to improve PFS-6, although a subset of patients appeared to derive benefit. Low levels of TMB and TIL density were typically observed. NANO assessment of neurologic function contributed to outcome assessment. Future studies may consider rationally designed combinatorial regimens.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bi WL, Nayak L, Meredith DM, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022. PMID: 34015129. doi:10.1093/neuonc/noab118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。